2022 MIPS Measures Relevant to Pathology

  1. Quality - 55% of total score:  Report 6 measures, including one Outcome or other High Priority measure for 12 months on at least 70% of eligible encounters to receive a score against 2022 National Benchmarks. Information about EMA (what happens if you report less than 6 measures) can be found here. Suggestions for your specialty include, but are not limited, to the following:   
    ID:
    249
    NQF:
    eMeasure ID:
    High Priority:
    No

    2022 MIPS Measure #249: Barrett’s Esophagus

    Percentage of esophageal biopsy reports that document the presence ofBarrett’smucosa that also include a statement about dysplasia

    Measure Type
    • Process
    Specifications
    Registry
    Specialty
    • Pathology
    Read more
    ID:
    250
    NQF:
    eMeasure ID:
    High Priority:
    No

    2022 MIPS Measure #250: Radical Prostatectomy Pathology Reporting

    Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status.

    Measure Type
    • Process
    Specifications
    Registry
    Specialty
    • Oncology/Hematology
    • Pathology
    Read more
    ID:
    395
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2022 MIPS Measure #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

    Pathology reports based on lung biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type following the International Association for the Study of Lung Cancer (IASLC) guidance or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report.

    Measure Type
    • Process
    Specifications
    Registry
    Specialty
    • Pathology
    Read more
    ID:
    396
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2022 MIPS Measure #396: Lung Cancer Reporting (Resection Specimens)

    Pathology reports based on lung resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type.

    Measure Type
    • Process
    Specifications
    Registry
    Specialty
    • Pathology
    Read more
    ID:
    397
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2022 MIPS Measure #397: Melanoma Reporting

    Pathology reports for primary malignant cutaneous melanoma that include the pT category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors.

    Measure Type
    • Process
    Specifications
    Registry
    Specialty
    • Pathology
    Read more
    ID:
    440
    NQF:
    eMeasure ID:
    High Priority:
    Yes

    2022 MIPS Measure #440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician

    Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results to the clinician within 7 days from the time when the tissue specimen was received by the pathologist.

    Measure Type
    • Process
    Specifications
    Registry
    Specialty
    • Dermatology
    • Pathology
    Read more
     
  2. IA: Improvement Activities - 15% of total score:  Attest that you completed up to 2 high-weighted activities or 4 medium-weighted activities for a minimum of 90 days. Groups with 15 or fewer participants or if you are in a rural or health professional shortage area,  attest that you completed 1 high-weighted or 2 medium-weighted activities for a minimum of 90 days. A group can attest to an activity when at least 50% of the clinicians in the group perform the same activity during any continuous 90-day period (or as specified in the activity description) in the same performance year.  The following are suggestions for your specialty:

Register with MDinteractive